Jose Davila-Torres, MD
Hematology & Oncology · Arecibo, PRNPI 1073613352
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Taiho Oncology, Inc. at 40.1% of the total. Reporting peaked in 2019 at $12,944 and has fallen 94.7% since, to $692 in 2025.
Across 214 payments — averaging $109.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Taiho Oncology, Inc.$9K
- E.r. Squibb & Sons, L.L.C.$7K
- Johnson & Johnson$3K
- AstraZeneca$544
- AbbVie$528
- PBG Puerto Rico LLC$419
- plus $3K from 27 others
What the payments were for
- Consulting fees$9,25940%
- Speaking & faculty fees$7,09030%
- Travel & lodging$2,28610%
- Food & beverage$4,77220%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Taiho Oncology, Inc. | 15 | $9,389 |
| E.r. Squibb & Sons, L.L.C. | 20 | $6,880 |
| Johnson & Johnson | 18 | $3,052 |
| AstraZeneca | 18 | $544 |
| AbbVie | 17 | $528 |
| PBG Puerto Rico LLC | 21 | $419 |
| Bristol Myers Squibb | 2 | $324 |
| Genentech USA, Inc. | 16 | $308 |
| Sanofi | 14 | $273 |
| Novartis | 11 | $255 |
| Eli Lilly Export S.A. Puerto Rico Branch | 8 | $208 |
| Amgen | 9 | $187 |
| ADC Therapeutics America, Inc. | 2 | $146 |
| Merck | 7 | $133 |
| Sobi, Inc | 6 | $116 |
| Deciphera Pharmaceuticals Inc. | 3 | $61 |
| Astellas Pharma US Inc | 3 | $60 |
| Zimmer Biomet | 1 | $60 |
| Exelixis Inc. | 3 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Gilead(2 entities) | 2 | $57 |
| GSK | 2 | $50 |
| CTI Biopharma Corp. | 2 | $45 |
| Array Biopharma Inc | 2 | $41 |
| Eisai Inc. | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| Incyte Corporation | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $20 |
| Caris MPI, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,433 in reported general payments places this provider in the 75th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 26 | $435,774 |
| IbrancePalbociclib | 24 | $383,681 |
| TasignaNilotinib Hcl | 12 | $241,652 |
| XtandiEnzalutamide | 14 | $198,574 |
| VenclextaVenetoclax | 11 | $169,043 |
| SprycelDasatinib | 12 | $122,831 |
| RetacritEpoetin Alfa-Epbx | 11 | $10,651 |
| Abiraterone Acetate | 16 | $8,332 |
| Anastrozole | 530 | $6,798 |
| Imatinib Mesylate | 27 | $6,065 |
| Famciclovir | 33 | $1,984 |
| Tamoxifen Citrate | 64 | $1,699 |
| Fentanyl | 11 | $1,429 |
| Sucralfate | 11 | $1,267 |
| SynthroidLevothyroxine Sodium | 19 | $1,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Retacrit | $22 | $394,33135 claims |
| NovartisTasigna | $255 | $241,65212 claims |
| Astellas Pharma US IncXtandi | $60 | $198,57414 claims |
| AbbVieVenclexta, Synthroid | $528 | $170,07330 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $6,880 | $122,83112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Arecibo
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Joel Lopez-FigueroaHumacao$163K
- Mirelis AcostaSan Juan$154K
- Luis Baez VallecilloSan Juan$107K
- Carlos Mendez SerranoCaguas$91K
- Santa MerleMoca$84K
- Edgardo Santiago-GuzmanSan Juan$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.